Last reviewed · How we verify
D-0120
D-0120 is a small molecule inhibitor of the PI3K delta subunit.
D-0120 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | D-0120 |
|---|---|
| Sponsor | InventisBio Co., Ltd |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, D-0120 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of immune cells. This leads to a decrease in the production of inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (PHASE2)
- Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (PHASE2)
- Evaluation of PK and Safety of D-0120 and Allopurinol (EARLY_PHASE1)
- D-0120 Safety and PK/PD Study in China (PHASE1, PHASE2)
- Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers (PHASE1)
- D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-0120 CI brief — competitive landscape report
- D-0120 updates RSS · CI watch RSS
- InventisBio Co., Ltd portfolio CI